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A BST R AC T   
 
Aim: COVID-19 disease has a broad spectrum ranging from asymptomatic course to death. While data show 
that the prognosis of the disease will be poor in the presence of comorbidity, we witness the death of patients 
with no comorbidities in our clinical practice. This study aimed to investigate the effect of comorbidity on the 
clinical course and mortality of COVID-19 pneumonia. 
Methods: 155 Rt-PCR (+) adult patients hospitalized at İzzet Baysal State Hospital (Bolu, Turkey) diagnosed 
with severe and critical pneumonia between August 2020 and February 2021 were included in this single-
center, retrospective study. The patients were divided into two groups with and without comorbidity, compared 
the severity of inflammation parameters, radiological involvement, and oxygen requirement, and evaluated 
their effects on mortality and hospitalization duration. 
Results:  There was no significant difference in the severity of the computed tomography (CT) involvement, 
the oxygen requirement, inflammation markers, and duration of hospitalization in patients with comorbidities 
compared to those without. When we evaluated the patients with comorbidities in general and their subgroups, 
the relationship with mortality was not significant. The severity of CT involvement, high oxygen requirement, 
and inflammation markers such as lymphocyte, lymphocyte ratio, LDH, CRP, troponin, ferritin levels were 
found to be associated with mortality.   
Conclusions:  In this study, we found that the presence of comorbidity did not affect mortality and duration 
of stay and that the severity of radiological involvement, the severity of hypoxemia, and the increase in 
inflammation markers were the determinants of mortality.   
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Introduction 
The COVID-19 pandemic has been in existence 
since the end of 2019, and the loss of life 
continues. The presence of comorbidity may 
affect the clinical course of COVID-19. 
Diseases such as type 2 diabetes mellitus (DM), 
hypertension (HT), atherosclerotic 
cardiovascular (CVS) diseases, and chronic 
obstructive pulmonary disease (COPD) 
increase the risk [1]. In some studies, HT (30%) 
[2] and in others, diabetes mellitus [3] is the 
most common comorbidity, causing high 
mortality rates. Although the prevalence of 
COPD is low, it exacerbates the clinical course 
and significantly increases mortality in its 
presence [4]. It was reported that cancer is not 
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common comorbidity in COVID-19 patients, 
and less mechanical ventilation requirement 
and mortality rates were reported in cancer 
cases [5]. In light of this information, we aimed 
to retrospectively investigate the frequency of 
comorbidities and the relationship of existing 
comorbidities with mortality and clinical course 
in Rt-PCR positive severe and critical 
hospitalized COVID-19 pneumonia patients. 
 
Materials and methods 
The single-center, retrospective study was 
performed with patients hospitalized in the 
inpatient clinic and intensive care unit of İzzet 
Baysal State Hospital. This study was approved 
by Abant İzzet Baysal University Ethics 
Committee (Date: 2021-10-06 / No:189).  
One hundred fifty-five patients with severe and 
critical pneumonia, according to WHO interim 
guidance [6], among Rt- PCR (+) COVID-19 
patients were included. Patients under the age 
of 18, pregnant and postpartum patients, 
patients with missing comorbidity information, 
CT, and laboratory parameters were excluded. 
Demographic, radiological (pulmonary 
involvement less than or above 50% in CT 
imaging), laboratory data, and treatment 
outcome of the patients were recorded 
retrospectively. The severity of oxygen 
requirement was grouped as mild (up to 5 L/min 
with the nasal cannula) and heavy (including 
mask, mask with reservoir, high flow nasal 
oxygen (HFNO), intubated follow up). Their 
comorbidities were grouped as HT, DM, 
DM+HT, chronic pulmonary disease (CPD), 
cardiovascular system diseases (CVSD), 
malignancy, connective tissue diseases (CDD), 
and other (such as goiter, chronic kidney 
failure, which we could not group).  
The analysis of the data obtained as a result of 
the research was performed in the SPSS 20 
statistical package program, and descriptive 
statistical methods (frequency, arithmetic 
mean, standard deviation, cross tables) were 
used. Compliance with normal distribution was 
evaluated with the Kolmogorov-Smirnov test. 
The arithmetic mean of the normally distributed 
groups was evaluated, and the Independent 
Sample t-test compared two independent 
groups. The medians of the non-normally 
distributed groups were determined, and the 
Mann-Whitney U test compared two 
independent groups, and the Chi-Square test 
examined the relationship between categorical 
variables. A p-value of <0.05 was considered 
statistically significant.   
 
Results  
The mean age of the patients was 68 years (31-
95), and the relationship between mortality and 
age was significant (61 years (31-95) in 
survivors, 70 years (48-94) in non-survivors, p: 
0.002). The group with comorbid diseases was 
older (69 (35-95) vs.  57.5 (31-94) p: 0.001). 
The overall comorbidity rate in the patients was 
73%, with HT 49.7%, DM 29%, DM+HT 
21.3%, CPD 14.8%, CVSD 9%, malignancy 
5.2%, CDD 1.9%, and 18.7% for other diseases 
(few diseases we did not group, such as goiter, 
chronic kidney disease). The rate of non-
comorbid patients was found to be 27.1%. 
When the patients with comorbidities were 
evaluated in general and according to their 
subgroups, the relationship with mortality was 
not statistically significant (p>0.005, Table 1). 
There was no significant difference in the 
severity of the CT involvement, the severity of 
the oxygen requirement, inflammation markers, 
and duration of stay in patients with 
comorbidities compared to those without 
(p>0.05, Table 2). In terms of duration of 
hospital stay, a significant difference was found 
only in the DM and DM+HT subgroups, with a 
shorter duration of stay. 
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Table 1. The relationship between the presence of comorbidity and mortality. 
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Non-comorbid   31/73.8 11/26.2 42/27.1 0.877 
* p<0.05 statistically significant, Chi-Square test. DM: diabetes mellitus, HT: hypertension, CVSD: cardiovascular system 
disease, CPD: chronic pulmonary disease CTD: connective tissue disease 
 
Table 2. Baseline demographics, CT involvement, and laboratory parameters of the study population classified 
by the presence of comorbidity. 











      Female 












     Mild 












     Below 50% 












      Exitus 










Age2 69 (35-95) 57.5 ( 31-94) 68 (31-95) 0.001 
Duration of hospitalization2 10 (1-55) 7 (3-60) 9 (1-60) 0.369 
Lymphocyte2 (0.9-3.4K/uL) 900 (200-3400) 950 (200-2600) 0.90 (0.20-3.40) 0.957 
Lymphocyte%2 (25-46 K/uL) 13.1 (1.9-49.3) 18 (1-36.2) 15.0 (1-49.3) 0.137 
CRP 2 (0-5 mg/L) 92.1 ( 2.2-139.4) 90.6 (7.40-132) 92.1 (2.20-139.4) 0.811 
LDH (1-248U/L) 336 ( 127-1884) 399.5 ( 183-885) 351 (127-1884) 0.147 
Troponin2 (12.6-20.7 ng/L) 9.9 (1.70-2327) 7 (1.6-1654) 9.4 (1.6-2327) 0.115 
Ferritin2  (23.9-366.2 ug/L) 233.7 (11.3-1500) 317 (21.4-1500) 245.9 ( 11.3-1500) 0.327 
Fibrinogen2 (170-420 mg/dL) 5.74 ( 1.47-10.25) 5.82 (2.79-11) 5.75 (1.47-11) 0.148 
D-Dimer2  (0-0.5 mg/L) 0.38 (0.03-17.1) 0.29 (0.02-7.70) 0.37 (0.02-17.1) 0.503 
 
CT: computed tomography. CRP: C-reactive protein. LDH: Lactate dehydrogenase. 
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When the survivor and the non-survivor group 
were compared, the severity of CT 
involvement, high levels of oxygen 
requirement, and laboratory parameters such as 
lymphocyte, lymphocyte ratio, lactate 
dehydrogenase (LDH), C-reactive protein 
(CRP), troponin, and ferritin were found to be 

































Oxygen requirement was high in 88% of those 
with CT involvement above 50% and 32.5% of 
those with CT involvement of less than 50% 
(p<0.05). A decrease in the lymphocytes and 
lymphocyte ratios and an increase in LDH, 
CRP, troponin, ferritin, D-dimer, and 
fibrinogen values were found to be significant 
in the group with severe CT involvement group 


































Table 3. Baseline demographics, CT involvement, and laboratory parameters of the study population classified 













      Female 












     Mild 












     Below 50% 













Age2 61( 31-95) 70(48-94) 68 (31-95) 0.002 
Duration of hospitalization2 7 (3-55) 22.5(1-60) 9(1-60) <0.001 
Lymphocyte2 (0.9-3.4K/uL) 1000 (200-3400) 600(200-2000) 0.90(0,20-3.40) <0.001 
Lymphocyte%2 (25-46 K/uL) 18.3(1,9-49.3) 9.45( 1-30.9) 15.0 (1-49.3) <0.001 
CRP2 (0-5 mg/L) 68.1 (2.2- 139.4) 123(3.5- 132.4) 92.1(2.2-139.4) <0.001 
LDH2 (1-248U/L) 337 (127- 1884) 422 (192-1375) 351(127-1884) 0.001 
Troponin2 (12.6-20.7 ng/L) 7.7 (1.6-1654.4) 18.4 (2.2-2327 9.4 (1.6-2327) <0.001 
Ferritin2 (23.9-366.2 ug/L) 214.3 (14.8-1500) 493.9(11.3-1500) 245.9(11.3-1500) <0.001 
Fibrinogen2 (170-420 g/dL) 5.67 (2.67-10.25) 5.95 (1.47-11) 5.75(1.47-11) 0.148 
D-dimer2 (0-0.5 mg/L) 0.39 (0.02-7.7) 0.33(0.03-17.1) 0.37(0.02-17.1) 0.123 
* p<0.05 statistically significant,    1Chi-Square test     2Mann-Whitney U test. CRP: C-reactive protein. LDH: 
Lactate dehydrogenase. 
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In a meta-analysis including ten studies in 
China, the mortality rate in COVID-19 was 5% 
[7], while in a Chinese Center for Disease 
Control and Prevention report containing 72314 
cases of COVID-19, the mortality was reported 
as 2.3%, 14.8% in patients over 80 years old, 
and 49% in critical cases [8]. In another study, 
the mortality rate in inpatient COVID-19 
patients reached 28.3% [2]. The overall 
mortality was 27% in our study.  
While the most common comorbidities in 






























(19%), and coronary heart disease (8%) [2], in 
patients with ARDS, they were HT (27%), DM 
(19%), and cardiovascular diseases (6%) [9]. 
Uçan et al. reported in their study that 62.1% of 
the patients had comorbidity, and hypertension 
was the most common [10]. In our study, 
comorbidity was observed in 73% of our 
patients, and in order of frequency, HT was 
49.7%, DM 29%, DM+HT 21.3%, CPD 14.8%, 
CVSD 9%, malignancy 5.2%, CDD 1.9%, other 
diseases (a few diseases that we did not group, 
such as goiter, chronic kidney failure) 18.7%, 
and the non-comorbid patient rate was 27.1%. 
Table 4.  Oxygen requirement and laboratory parameters of the study population classified by the severity of 
CT involvement. 












    Mild    












Duration of hospitalization2 7 (3-31) 16 (1-60) 9 (1-60) <0.001 
Lymphocyte2 
(0.9-3.4K/uL) 
1.30 (0.20-3.40) 0.70 (0.20-2.60) 0.90 (0,20-3.40) <0.001 
Lymphocyte%2 
(25-46 K/uL) 
19.6 (1.90-49.3) 9.3 (1-30.9) 15.0 (1-49.3) <0.001 
CRP2 
(0-5 mg/L) 






291 (172-868) 440 (127-1884) 351 (127-1884) <0.001 
Troponin2 
(12.6-20.7 ng/L) 
7.2 (1.6-203) 12.7 (1.7-2327) 9.4 (1.6-2327) < 0.001 
Ferritin2  
(23.9-366.2 ug/L) 






5.22 (1.47-9.9) 6.4 (2.02-11) 5.75 (1.47-11) < 0.001 
D-Dimer2  
(0-0.5 mg/L) 
0.31 (0.04-4.95) 0.46 (0.02-17.1) 0.37 (0.02-17.1) 0.014 
* p<0.05 statistically significant.    1Chi-Square test.     2Mann-Whitney U test. 
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However, when we grouped the diseases as 
presence/absence of comorbid diseases and 
grouped them individually, no relation was 
found with mortality (p>0.05). 
Angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin receptor blockers 
(ARB) increase ACE2, and virus binding also 
increases [11,12]. The increased soluble ACE2 
in the circulation can bind SARS-CoV-2, 
reducing its ability to damage the lungs and 
other ACE2-bearing organs [13]. Therefore, 
ACE inhibitors and ARBs may reduce the 
potential for patients with COVID19 to develop 
acute respiratory distress syndrome, 
myocarditis, or acute kidney injury. ARBs have 
been proposed as a treatment for COVID-19 
and its complications [14]. There is no evidence 
yet that hypertension is associated with the 
consequences of COVID-19 or that the use of 
ACE inhibitors or ARBs during the COVID-19 
pandemic is harmful or, therefore, beneficial 
[15]. In our study, no increase was found in 
mortality in patients with HT. No prolongation 
of hospitalization was observed (8 days (1-55) 
in the group with HT vs. 9.5 days (3-60) in the 
non-HT group, p:0.310). 
In the study of Mithal et al., 47.1% of the 
hospitalized COVID-19 patients had Diabetes, 
and it was found to be associated with severe 
illness and mortality. HT was reported as the 
most common comorbidity in patients with DM 
[16]. In another study, DM was reported as the 
most common comorbidity in COVID-19 and 
was associated with mortality [3]. Mortality 
rates of 7.3% [8] have been reported in diabetic 
patients in China and over 30% in Europe [17]. 
Although the mechanism underlying the 
relationship between diabetes and COVID-19 
severity remains unclear, Yang et al.[18] 
indicated that ACE2 could be strongly 
expressed in pancreatic islet cells, suggesting 
that these cells may be targeted by SARS-CoV-
2 [19]. Metabolic disorders may impair 
macrophage and lymphocyte function, resulting 
in poor immune function [20] and may make 
individuals more susceptible to disease 
complications [21]. Diabetes COVID-19 has 
also been associated with increased severity of 
complications and symptoms [22]. This may be 
partly due to increased risk of endothelial 
dysfunction, increased systemic inflammatory 
response, micro-and macrovascular disease, 
and diabetic cardiomyopathy [23,24,35,26].  
Despite the presence of DM in 31-80% of those 
who died due to COVID-19 in studies [16,17], 
DM was associated with ICU hospitalization 
and duration of hospitalization in the 
multivariate analysis, but no correlation with 
mortality was demonstrated [28].    
In the study of Guo et al, higher CRP, ferritin, 
interleukin-6 (IL-6), sedimentation levels were 
found, and Zhu et al. found an increase in the 
incidence of lymphopenia, higher CRP, and 
procalcitonin levels in diabetic patients [29,30]. 
In our study, we did not determine increased 
mortality in patients with diabetes. At the same 
time, oxygen requirement was not high, and CT 
involvement was not more severe in this group. 
Also, we did not detect increased inflammation 
parameters. For these possible reasons, the 
duration of hospitalization was also found to be 
shorter (8 days (1-31) in the diabetes group vs. 
10 days (3-60) in the non-diabetes group, p: 
0.052).  
In their study, which included 1590 
hospitalized COVID-19 patients, Guan et al. 
reported that the most common comorbidities 
among infected individuals were hypertension 
(16.9%) and diabetes (8.2%), and patients with 
two or more comorbidities (8.2%) [31]. In 
another study, 149 of 1138 patients (13.09%) 
had two comorbidities, and hypertension+DM 
was the most commonly observed comorbid 
disease. The co-existence of more than one 
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comorbidity significantly increased the risk of 
death. In multivariate analysis, more than four 
times mortality risk was observed in patients 
with more than three comorbidities. Age-
classified analysis revealed that the effect of 
comorbidities on death decreased with 
increasing age [32]. In our study, the 
association of DM + HT was 21.3%, and its 
relationship with mortality was not significant, 
but the length of hospital stay was found to be 
significantly shorter (DM+HT co-existence 7 
days (1-31) vs. non-DM+HT 10 days (3-60), p: 
0.031). While the expected issue was the 
prolonged duration of hospitalization, the fact 
that the oxygen requirement was not high, the 
CT involvements were not severe, and the 
inflammation markers were not high in these 
comorbid groups may explain this result.  
Although the prevalence of COPD is low in 
COVID-19, these patients' mortality and severe 
disease rates have been reported to be high [4]. 
Viral infections cause an increase in systemic 
inflammation in COPD patients [33,34]. 
Comorbid conditions, which are usually 
associated with COPD patients, may also be 
associated with increased hospitalization 
[35,36].  
Questions remain about the effects of inhaled 
(ICS) and systemic corticosteroids, short- and 
long-acting β2-agonists, and short- and long-
acting muscarinic antagonists in alleviating or 
exacerbating COVID-19. ACE-2 expression in 
airway epithelial cells from patients with 
asthma is reduced in those receiving ICS 
compared to those not using ICS, raising the 
possibility that ICS exposure may reduce viral 
entry. It is not clear that the same relationship is 
valid in the COPD airway, which increases 
susceptibility to pneumonia following ICS use 
[37]. In our study, no significant relationship 
was found between the presence of COPD and 
mortality.  
Asthma comorbidity was found to be more 
common in non-severe cases of COVID-19. 
Compared with patients with asthma, COPD 
patients were found to have increased mortality 
and a higher risk of developing severe disease 
and ARDS. In this study, downregulation of 
ACE2 protein expression in the lower airways 
was found in asthmatics compared to controls 
and patients with COPD. Besides, asthmatics 
with higher peripheral blood eosinophilia show 
lower ACE2 expression, indicating potential 
regulation of ACE2 expression by type 2 
inflammation in asthmatics [38]. Our study 
created a chronic pulmonary disease category, 
including interstitial lung disease without 
distinction between asthma and COPD. In this 
group, no increase in mortality and n prolonged 
hospitalization (8 days (4-31) in the group with 
CPD vs. 10 days (1-60) in the group without 
CPD) were observed (p>0.005). 
When patients with CVSD have COVID-19, 
the rate of complications such as myocardial 
infarction, malignant arrhythmia, mesenteric 
infarction, cardiovascular death, heart failure, 
myocardial suppression increases [39]. 
COVID-19 is associated with endothelitis and 
myocarditis [40,41]. It is believed that SARS 
CoV-2 can elicit an intense systemic 
inflammatory response, and the atherosclerotic 
plaque may become unstable and more prone to 
rupture, leading to higher myocardial infarction 
rates and faster systolic dysfunction and heart 
failure [42]. However, in our ASCVD group, 
which consisted of 14 patients, no increase in 
mortality and no prolonged hospitalization (8 
days (4-19) in patients with ASCVD vs. 9 days 
(1-60) in patients without ASCVD) were 
determined (p>0.05).  
In the study of Jarahzadeh et al., cancer was not 
among the most common comorbidities in 
confirmed COVID-19 patients [5]. A lower rate 
of mechanical ventilation or death has been 
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reported in patients with cancer infected with 
COVID-19 than in patients without cancer [5]. 
In a nationwide study including 1590 
hospitalized COVID-19 patients, Guan et al. 
reported that 18 cases (1.1%) had a history of 
malignancy [31]. In another study, those with a 
history of malignancy were found to be 6% 
[43]. A meta-analysis showed that 2% of 
COVID-19 patients had a history of 
malignancy, with a higher risk of severe 
symptoms in the cancer group with a history of 
chemotherapy or surgery within one month 
(75% vs. 43%) [44].  
In COVID-19 patients with lung cancer, higher 
disease severity and higher rates of intensive 
care admission and mechanical ventilation 
requirement have been reported compared to 
other malignancies and the general population 
[45]. Multicenter studies have reported a high 
mortality rate of 33% in thoracic malignancies 
[46]. In our study, patients with cancer were 
few, and there was no significant difference in 
terms of mortality and hospitalization (22.5 (3-
45) days in the cancer group, 9 (1-60) days in 
the non-cancer group) (p>0.05). Although the 
number of our patients was low in terms of 
connective tissue diseases, we did not find any 
effect on mortality and duration of stay (9 days 
(1-60) in non-CDD patients vs. 24 days (14-27) 
in patients with CDD) (p>0.05).  
In the study conducted by Uçan et al., the mean 
age was reported as 61.9±20.1 years [10]. In our 
study, the mean age of the patients was 68 years 
(31-95), and the relationship between mortality 
and age was statistically significant (61 years 
(31-95) in survivors vs. 70 years (48-94) in non-
survivors, p: 0.002). The group with comorbid 
diseases was older. (69 years (35-95) vs. 57.5 
years (31-94), p: 0.001). An analysis of 77,932 
patients (41510 men) infected with COVID-19 
indicated that men had 1.71 times higher 
mortality rate than women [47]. The fact that 
genetic factors or risk-increasing factors such as 
diabetes, hypertension, and coronary artery 
disease are more common in men may explain 
this increase [1]. The increased smoking rate in 
men may also be associated with increased 
mortality [48]. Also, the stronger immune 
system of women and the location of most of 
the genes that regulate immunity on the X 
chromosome may have turned this ratio in favor 
of women [49]. Biological gender is also related 
to T cells and autoimmune response; for 
example, women secrete higher amounts of 
interferon than men [50] while testosterone 
suppresses immunity, estrogens activate it [51]. 
Similar to the male dominance in the literature8, 
59.3% of all patients in our study consisted of 
men. Comorbid diseases were not more 
common in males, and no gender difference 
was found in mortality rates (p>0.05).  
In the study of Uçan et al., Ferritin, CRP, 
troponin, d-dimer, LDH, and 
neutrophil/lymphocyte ratio were found to be 
high in the mortal group [10]. In our study, 
lymphocyte, lymphocyte ratio, LDH, CRP, 
troponin, ferritin were also associated with 
mortality (p>0.005), but no significant 
correlation was found with fibrinogen and d-
dimer (p>0.05).   
Xie et al. stated that dyspnea and hypoxia 
despite oxygen support at admission were 
strong independent predictors of mortality. 
99% of patients with an oxygen saturation level 
of 90% or more survived, while 69% of those 
with oxygen saturation of 90% or less despite 
oxygen support died [52]. In our study, it was 
the increase in oxygen requirement that affected 
mortality (p>0.005). Chatterjee et al. also found 
higher mortality in hospitalized COVID-19 
patients with oxygen saturation of <92% or 
respiratory rate of >22/min [53].     
Higher CRP values were found in severe 
pneumonia with diffuse involvement. In these 
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patients, the duration of stay in the intensive 
care unit, ventilator support, and mortality rates 
was also found to be higher [54]. In our study, 
CT involvement of over 50% was found to be 
associated with mortality (p>0.005). Oxygen 
requirement was high in 88% of those with CT 
involvement above 50% and 32.5% of those 
with CT involvement of less than 50% 
(p<0.05). A decrease in lymphocytes and 
lymphocyte ratios and an increase in LDH, 
CRP, troponin, ferritin, D-dimer, and 
fibrinogen values were significant in the group 
with severe CT involvement compared to the 
other group (p<0.05).  
 
Conclusions 
Most of our patients were patients followed up 
with critical pneumonia (92 out of 155 patients 
(59.4%) had severe oxygen requirement, 75 
(48.4%) had more than 50% CT involvement). 
We found that the presence of comorbidity did 
not affect mortality, while CT involvement and 
oxygen requirement were associated with 
mortality. Among the laboratory parameters, 
we found that lymphocyte, lymphocyte ratio, 
LDH, CRP, troponin, and ferritin were 
associated with mortality. Patients with severe 
CT involvement had higher oxygen 
requirements and higher inflammation markers.  
Limitations of our study are that results should 
be replicated with larger and more 
representative samples. In particular, the 
number of our malignancy and CDD group was 
low, and more extensive studies are required.  
Another limitation is the study population 
consisting of inpatients only. In terms of 
hospitalization, advanced age and the presence 
of comorbidity should be taken as criteria 
without hypoxemia, the severity of CT 
involvement, and abnormal laboratory 
parameters. 
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